Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15

Addiction

Volumn 110, Issue 12, 2015, Pages 1941-1950

  Niesink, Raymond J M ^a,b   Rigter, Sander ^a   Koeter, Maarten W ^c   Brunt, Tibor M ^a,c  

^a NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^b OPEN UNIVERSITY OF THE NETHERLANDS   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cannabidiol; Cannabinol; Hashish; Herbal cannabis; Marijuana; Nederwiet; Potency; 9 tetrahydrocannabinol

Indexed keywords

CANNABIDIOL; CANNABINOL; CANNABIS; DRONABINOL; PSYCHOTROPIC AGENT;

CHEMISTRY; GAS CHROMATOGRAPHY; NETHERLANDS; TIME FACTOR;

CANNABIDIOL; CANNABINOL; CANNABIS; CHROMATOGRAPHY, GAS; DRONABINOL; NETHERLANDS; PSYCHOTROPIC DRUGS; TIME FACTORS;

EID: 84947038038     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13082     Document Type: Article

References (43)

1. Potter D. J., Clark P., Brown M. B. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 2008; 53: 90-4.
2. McLaren J., Swift W., Dillon P., Allsop S. Cannabis potency and contamination: a review of the literature. Addiction 2008; 103: 1100-9.
3. Mehmedic Z., Chandra S., Slade D., Denham H., Foster S., Patel A. S. et al. Potency trends of delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 2010; 55: 1209-17.
4. Pijlman F. T., Rigter S. M., Hoek J., Goldschmidt H. M., Niesink R. J. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biol 2005; 10: 171-80.
5. King L. A., Carpentier C., Griffiths P. Cannabis potency in Europe. Addiction 2005; 100: 884-6.
6. Cascini F., Aiello C., Di Tanna G. Increasing delta-9-tetrahydrocannabinol (delta-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 2012; 5: 32-40.
7. Monshouwer K., van Laar M., Vollebergh W. A. Buying cannabis in 'coffee shops'. Drug Alcohol Rev 2011; 30: 148-56.
8. MacCoun R. J. What can we learn from the Dutch cannabis coffeeshop system? Addiction 2011; 106: 1899-910.
9. Korf D. J. An open front door: the coffee shop phenomenon in the Netherlands. In: Rödner Snitzman S., Olsson B., Room R., editors. A Cannabis Reader: Global Issues and Local Experiences. Lisbon: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2008, pp. 137-54.
10. Niesink R. J., van Laar M. W. Does cannabidiol protect against adverse psychological effects of THC? Front Psychiatry 2013; 4: 130.
11. Lemmens P. Dutch cannabis policy evaluated. Addiction 2002; 97: 119-20.
12. Hunault C. C., Mensinga T. T., Bocker K. B., Schipper C. M., Kruidenier M., Leenders M. E. et al. Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology (Berl) 2009; 204: 85-94.
13. Di Forti M., Morgan C., Dazzan P., Pariante C., Mondelli V., Marques T. R. et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009; 195: 488-91.
14. Di Forti M., Sallis H., Allegri F., Trotta A., Ferraro L., Stilo S. A. et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 2014; 40: 1509-17.
15. Bieleman B., Nijkamp R., Reimer J., Haaijer M. Coffeeshops in Nederland 2012: Aantallen coffeeshops en gemeentelijk beleid 1999-2012 [Coffeeshops in the Netherlands 2012: Numbers of Coffeeshops and Local Policy]. Groningen, the Netherlands: Bureau Intraval; 2013.
16. United Nations Office on Drugs and Crime Recommended Methods for the Identification and Analysis of Cannabis and Cannabis Products (revised and updated): Manual For Use By National Drug Analysis Laboratories. New York: United Nations Publications; 2009.
17. Clarke R. C. Sinsemilla heritage: what is in a name?. In: King J., editor. The Cannabible. Berkeley, CA: Ten Speed Press; 2001; 45: 1-24.
18. Sevigny E. L. Is today's marijuana more potent simply because it's fresher? Drug Test Anal 2013; 5: 62-7.
19. Tsumura Y., Aoki R., Tokieda Y., Akutsu M., Kawase Y., Kataoka T. et al. A survey of the potency of Japanese illicit cannabis in fiscal year 2010. Forensic Sci Int 2012; 221: 77-83.
20. Zamengo L., Frison G., Bettin C., Sciarrone R. Variability of cannabis potency in the Venice area (Italy): a survey over the period 2010-2012. Drug Test Anal 2014; 6: 46-51.
21. Zamengo L., Frison G., Bettin C., Sciarrone R. Cannabis potency in the Venice area (Italy): update 2013. Drug Test Anal 2014; 7: 255-58.
22. Hazekamp A., Fischedick J. T. Cannabis-from cultivar to chemovar. Drug Test Anal 2012; 4: 660-7.
23. van der Pol P., Liebregts N., de Graaf R., Korf D. J., van den Brink W., van Laar M. Validation of self-reported cannabis dose and potency: an ecological study. Addiction 2013; 108: 1801-8.
24. King L. Understanding Cannabis Potency and Monitoring Cannabis Products in Europe, EMCDDA Monographs, Vol. 242. Luxembourg: Publications Office of the European Union; 2008.
25. Rosenthal E. The Big Book of Buds. Oakland, CA: Quick American Archives; 2001.
26. Clarke R. C., Merlin M. D. Cannabis: Evolution and Ethnobotany. Berkeley, CA: University of California Press; 2013.
27. Raharjo T. J., Verpoorte R. Methods for the analysis of cannabinoids in biological materials: a review. Phytochem Anal 2004; 15: 79-94.
28. de Meijer E. P., Bagatta M., Carboni A., Crucitti P., Moliterni V. C., Ranalli P. et al. The inheritance of chemical phenotype in Cannabis sativa L. Genetics 2003; 163: 335-346.
29. Niesink R. J., van Laar M. W. Does cannabidiol protect against adverse psychological effects of THC? Front Psychiatry 2013; 4: 130.
30. Bossong M. G., Niesink R. J. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol 2010; 92: 370-85.
31. Moore T. H., Zammit S., Lingford-Hughes A., Barnes T. R., Jones P. B., Burke M. et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319-28.
32. Hall W., Degenhardt L. High potency cannabis: a risk factor for dependence, poor psychosocial outcomes, and psychosis. BMJ 2015; 350: h1205.
33. Schubart C. D., Sommer I. E., van Gastel W. A., Goetgebuer R. L., Kahn R. S., Boks M. P. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 2011; 130: 216-21.
34. Morgan C. J., Freeman T. P., Schafer G. L., Curran H. V. Cannabidiol attenuates the appetitive effects of delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 2010; 35: 1879-85.
35. van der Pol P. M. The dynamics of cannabis use and dependence. Amsterdam: Dissertation University of Amsterdam; 2014.
36. Ross S. A., ElSohly M. A. CBN and{increment} 9-THC concentration ratio as an indicator of the age of stored marijuana samples. Bull Narc 1997; 49: 139.
37. ElSohly M. A., Ross S. A., Mehmedic Z., Arafat R., Yi B., Banahan B. F., III Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci 2000; 45: 24-30.
38. Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 2015; 110: 19-35.
39. Fergusson D. M., Boden J. M. Cannabis use and later life outcomes. Addiction 2008; 103: 969-76.
40. Meier M. H., Caspi A., Ambler A., Harrington H., Houts R., Keefe R. S. et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 2012; 109: E2657-64.
41. Patton G. C., Coffey C., Carlin J. B., Degenhardt L., Lynskey M., Hall W. Cannabis use and mental health in young people: cohort study. BMJ 2002; 325: 1195-8.
42. Schubart C. D., van Gastel W. A., Breetvelt E. J., Beetz S. L., Ophoff R. A., Sommer I. E. et al. Cannabis use at a young age is associated with psychotic experiences. Psychol Med 2011; 41: 1301-10.
43. Morgan C. J., Curran H. V. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008; 192: 306-7.